Representative Reduction in Cerebral Amyloid Deposition in a Patient Treated with Lecanemab Over 12 Months (IMAGE)

Chinese Medical Journals Publishing House Co., Ltd.

Representative Reduction in Cerebral Amyloid Deposition in a Patient Treated with Lecanemab Over 12 Months

Caption

Serial Aβ-PET scans are displayed at baseline (top row) to 6 months (middle row) and 12 months (bottom row) of treatment. For each time point, the right lateral surface view (left column) and the left lateral surface view (right column) are displayed. Aβ deposition is represented as Z-scores, indicating the number of standard deviations from the mean of a cognitively normal reference cohort. The color scale ranges from –2 to 4, where values near zero (green) reflect normal Aβ levels, and positive values (yellow/red) represent abnormal accumulation. Progressive reduction in Z-scores across time points illustrates amyloid clearance in response to lecanemab. Aβ-PET: Aβ positron emission tomography.

Credit

Chinese Medical Journal | Source link: https://journals.lww.com/cmj/fulltext/2025/11200/safety_and_effectiveness_of_lecanemab_in_chinese.7.aspx

Usage Restrictions

Credit must be given to the creator. Only noncommercial uses of the work are permitted. No derivatives or adaptations of the work are permitted.

License

CC BY-NC-ND

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.